Clinical Trial: Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752550) titled 'Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer' on Aug. 04.

Brief Summary: To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.

Study Start Date: July 30

Study Type: INTERVENTIONAL

Condition: Triple-Negative Breast Cancer (TNBC)

Intervention: DRUG: Retlirafusp alfa+Nab-paclitaxel:

Retlirafusp alfa+Nab-paclitaxel

DRUG: Retlirafusp alfa+Fluzoparib

Retlirafusp alfa+Fluzoparib

DRUG: Retlirafusp alfa+TP-AC

Retlirafusp alfa+TP-AC

DRUG: Retlirafusp alfa+Fluzoparib

Retlira...